Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among intrinsic subtypes of breast cancer. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848376/
https://www.ncbi.nlm.nih.gov/pubmed/31750258
http://dx.doi.org/10.3389/fonc.2019.01178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848376/
https://www.ncbi.nlm.nih.gov/pubmed/31750258
http://dx.doi.org/10.3389/fonc.2019.01178

Ejemplares similares